1. Home
  2. KNRX vs BOLD Comparison

KNRX vs BOLD Comparison

Compare KNRX & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KNRX

KNOREX LTD. Class A Ordinary Shares

N/A

Current Price

$0.86

Market Cap

27.4M

Sector

Technology

ML Signal

N/A

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.15

Market Cap

25.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNRX
BOLD
Founded
2009
2018
Country
Singapore
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
27.4M
25.7M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
KNRX
BOLD
Price
$0.86
$1.15
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
4.8M
113.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
90.53
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.76
$0.96
52 Week High
$3.45
$1.79

Technical Indicators

Market Signals
Indicator
KNRX
BOLD
Relative Strength Index (RSI) 43.10 47.53
Support Level $0.77 $1.15
Resistance Level $2.05 $1.20
Average True Range (ATR) 0.37 0.03
MACD -0.02 0.00
Stochastic Oscillator 5.11 50.00

Price Performance

Historical Comparison
KNRX
BOLD

About KNRX KNOREX LTD. Class A Ordinary Shares

Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. Its software offers marketers cost-effective solutions and productivity-enhancing capabilities to target audience across various advertising channels and devices through automated processes and algorithms, which is known as programmatic advertising. Its product, Knorex XPOSM, is a self-service enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications. The Company operates in one operating segment, which focuses on platform subscription fee, platform services, managed activations, and professional services.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Share on Social Networks: